Prolonged duration of action of suxamethonium in pregnant and postpartum patients: A registry study.
butyrylcholinesterase
neuromuscular blockade
postpartum
pregnancy
pseudocholinesterase
suxamethonium
Journal
Acta anaesthesiologica Scandinavica
ISSN: 1399-6576
Titre abrégé: Acta Anaesthesiol Scand
Pays: England
ID NLM: 0370270
Informations de publication
Date de publication:
24 Mar 2024
24 Mar 2024
Historique:
revised:
16
01
2024
received:
13
10
2023
accepted:
10
03
2024
medline:
25
3
2024
pubmed:
25
3
2024
entrez:
24
3
2024
Statut:
aheadofprint
Résumé
Suxamethonium is hydrolysed by butyrylcholinesterase (BChE) and a low BChE activity can result in a prolonged duration of action of suxamethonium. The BChE activity is reduced during pregnancy and postpartum period by up to 33%. However, it can also be reduced by mutations in the BChE gene. In this study, we assessed BChE activity and mutations in the BChE gene in pregnant and postpartum patients with prolonged duration of action of suxamethonium. It was hypothesised that at least 30% of patients with a low BChE activity did not have a mutation in the BChE gene. In this registry study we focused on pregnant and postpartum patients with a history of prolonged duration of action of suxamethonium referred to the Danish Cholinesterase Research Unit (DCRU) between March 2007 and January 2023. Primary outcome was the proportion of patients without a mutation among patients with a low BChE activity. Secondary outcomes were the proportion of patients with a low BChE activity and the proportion of patients with a mutation out of the total number of patients. A total of 40 patients were included and among patients with a low BChE activity, 6% (95% CI: 1%-21%) did not have a mutation. Out of the total number of included patients referred to the DCRU, 90% (95% CI: 76%-97%) had a mutation and 94% (95% CI: 80%-99%) had a low BChE activity. Among pregnant and postpartum patients with a history of prolonged duration of action of suxamethonium and a low BChE activity, 6% did not have a mutation in the BChE gene. Our findings suggest that during pregnancy and postpartum clinically relevant prolonged duration of action of suxamethonium rarely occurs in genotypically normal patients.
Sections du résumé
BACKGROUND
BACKGROUND
Suxamethonium is hydrolysed by butyrylcholinesterase (BChE) and a low BChE activity can result in a prolonged duration of action of suxamethonium. The BChE activity is reduced during pregnancy and postpartum period by up to 33%. However, it can also be reduced by mutations in the BChE gene. In this study, we assessed BChE activity and mutations in the BChE gene in pregnant and postpartum patients with prolonged duration of action of suxamethonium. It was hypothesised that at least 30% of patients with a low BChE activity did not have a mutation in the BChE gene.
METHODS
METHODS
In this registry study we focused on pregnant and postpartum patients with a history of prolonged duration of action of suxamethonium referred to the Danish Cholinesterase Research Unit (DCRU) between March 2007 and January 2023. Primary outcome was the proportion of patients without a mutation among patients with a low BChE activity. Secondary outcomes were the proportion of patients with a low BChE activity and the proportion of patients with a mutation out of the total number of patients.
RESULTS
RESULTS
A total of 40 patients were included and among patients with a low BChE activity, 6% (95% CI: 1%-21%) did not have a mutation. Out of the total number of included patients referred to the DCRU, 90% (95% CI: 76%-97%) had a mutation and 94% (95% CI: 80%-99%) had a low BChE activity.
CONCLUSION
CONCLUSIONS
Among pregnant and postpartum patients with a history of prolonged duration of action of suxamethonium and a low BChE activity, 6% did not have a mutation in the BChE gene. Our findings suggest that during pregnancy and postpartum clinically relevant prolonged duration of action of suxamethonium rarely occurs in genotypically normal patients.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Department of Anaesthesia, Centre of Head and Orthopaedics, Rigshospitalet
Informations de copyright
© 2024 The Authors. Acta Anaesthesiologica Scandinavica published by John Wiley & Sons Ltd on behalf of Acta Anaesthesiologica Scandinavica Foundation.
Références
Jensen AG, Callesen T, Hagemo JS, Hreinsson K, Lund V, Nordmark J. Scandinavian clinical practice guidelines on general anaesthesia for emergency situations. Acta Anaesthesiol Scand. 2010;54:922‐950.
Fuchs‐Buder T, Romero CS, Lewald H, et al. Peri‐operative management of neuromuscular blockade: a guideline from the European Society of Anaesthesiology and Intensive Care. Eur J Anaesthesiol. 2023;40:82‐94.
Guay J, Grenier Y, Varin F. Clinical pharmacokinetics of neuromuscular relaxants in pregnancy. Clin Pharmacokinet. 1998;34:483‐496.
Baron TH, Ramirez B, Richter JE. Gastrointestinal motility disorders during pregnancy. Ann Intern Med. 1993;118:366‐375.
Evans FT, Gray PWS, Lehmann H, Silk E. Sensitivity to succinylcholine in relation to serum‐cholinesterase. Lancet. 1952;1:1229‐1230.
Viby‐Mogensen J. Correlation of succinylcholine duration of action with plasma cholinesterase activity in subjects with the genotypically normal enzyme. Anesthesiology. 1980;53:517‐520.
Ritter DM, Rettke SR, Ilstrup DM, Burritt MF. Effect of plasma cholinesterase activity on the duration of action of succinylcholine in patients with genotypically normal enzyme. Anesth Analg. 1988;67:1123‐1126.
Vanlinthout LEH, Van Egmond J, De Boo T, Lerou JGC, Wevers RA, Booij LHDJ. Factors affecting magnitude and time course of neuromuscular block produced by suxamethonium. Br J Anaesth. 1992;69:29‐35.
Naguib M, Brull SJ, Johnson KB. Conceptual and technical insights into the basis of neuromuscular monitoring. Anaesthesia. 2017;72:16‐37.
Viby‐Mogensen J. Succinylcholine neuromuscular blockade in subjects heterozygous for abnormal plasma cholinesterase. Anesthesiology. 1981;55:231‐235.
Davis L, Britten JJ, Morgan M. Cholinesterase its significance in anaesthetic practice. Anaesthesia. 1997;52:244‐260.
Lockridge O. Review of human butyrylcholinesterase structure, function, genetic variants, history of use in the clinic, and potential therapeutic uses. Pharmacol Ther. 2015;148:34‐46.
Evans RT, Wroe JM. Plasma cholinesterase changes during pregnancy: their interpretation as a cause of suxamethonium‐induced apnoea. Anaesthesia. 1980;35:651‐654.
Hazel B, Monier D. Human serurm cholinesterase: variations during pregnancy and post‐partum. Can Anaesth Soc J. 1971;18:272‐277.
Robertson GS. Serum cholinesterase deficiency II: pregnancy. Br J Anaesth. 1966;38:361‐369.
Shinder SM. Serum cholinesterase activity during pregnancy, labor and the puerperium. Anesthesiology. 1965;26:335‐339.
Whittaker M. Plasma cholinesterase variants and the anaesthetist. Anaesthesia. 1980;35:174‐197.
Jensen FS, Skovgaard LT, Viby‐Mogensen J. Identification of human plasma cholinesterase variants in 6,688 individuals using biochemical analysis. Acta Anaesthesiol Scand. 1995;39:157‐162.
Thomsen JL, Nielsen CV, Palmqvist DF, Gätke MR. Premature awakening and underuse of neuromuscular monitoring in a registry of patients with butyrylcholinesterase deficiency. Br J Anaesth. 2015;115:i89‐i94.
El‐Orbany MI, Joseph NJ, Salem MR, Klowden AJ. The neuromuscular effects and tracheal intubation conditions after small doses of succinylcholine. Anesth Analg. 2004;98:1680‐1685.
Soliday FK, Conley YP, Henker R. Pseudocholinesterase deficiency: a comprehensive review of genetic, acquired, and drug influences. AANA J. 2010;78:313‐320.
Mintjens N, Brummans R, Soetens F, Claes KBM, Vanlinthout LE. Timing of blood sampling for butyrylcholinesterase phenotyping in patients with prolonged neuromuscular block after mivacurium or suxamethonium. Acta Anaesthesiol Scand. 2021;65:182‐187.
Leighton BL, Cheek TG, Gross JB, et al. Succinylcholine pharmacodynamics in peripartum patients. Anesthesiology. 1986;64:202‐205.
Ravindran RS, Cummins DF, Pantazis KL, Strausburg BJ, Baenziger JC. Unusual aspects of low levels of pseudocholinesterase in a pregnant patient. Anesth Analg. 1982;61:953‐955.
Davies P, Landy M. Suxamethonium and mivacurium sensitivity from pregnancy‐induced plasma cholinesterase deficiency. Anaesthesia. 1998;53:1109‐1111.
Wildsmith JAW. Serum pseudocholinesterase, pregnancy and suxamethonium. Anaesthesia. 1972;27:90‐91.
Weissman DB, Ehrenwerth J. Prolonged neuromuscular blockade in a parturient associated with succinylcholine. Anesth Analg. 1983;62:444‐446.
Ellison M, Grose B, Howell S, Wilson C, Lenz J, Driver R. Prolonged paralysis following emergent cesarean section with succinylcholine despite normal dibucaine number. West Virginia Medial J. 2016;112:44‐46.
Thomsen JL, Nielsen CV, Eskildsen KZ, Demant MN, Gätke MR. Awareness during emergence from anaesthesia: significance of neuromuscular monitoring in patients with butyrylcholinesterase deficiency. Br J Anaesth. 2015;115:i78‐i88.
Odor PM, Bampoe S, Lucas DN, Moonesinghe SR, Andrade J, Pandit JJ. Incidence of accidental awareness during general anaesthesia in obstetrics: a multicentre, prospective cohort study. Anaesthesia. 2021;76:759‐776.